Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS
2026 · third_quarter · Q3
Issues related to the Rare Pediatric Disease Priority Review Voucher (PRV) Program; Rare disease drug development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS
2026 · first_quarter · Q1
Source: Senate LDA
| THERMO FISHER SCIENTIFIC |
| 2 |
| 2024 |
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development
DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS
2025 · fourth_quarter · Q4
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development
DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS
2025 · third_quarter · Q3
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development
DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS
2025 · second_quarter · Q2
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development
DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS
2025 · first_quarter · 1A
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development
DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS
2025 · first_quarter · Q1
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development
DENALI THERAPEUTICS via MANATT, PHELPS, AND PHILLIPS
2025 · first_quarter · RR
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development
MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · Q4
Regulation of in vitro diagnostics and lab-developed tests
MAYO CLINIC via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · RA
Regulation of in vitro diagnostics and lab-developed tests
KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · Q4
Regulation of in vitro diagnostics and lab-developed tests
ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · Q4
Regulation of in vitro diagnostics and lab-developed tests
THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · Q4
Regulation of in vitro diagnostics and lab-developed tests
COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · Q4
Regulation of in vitro diagnostics and lab-developed tests
ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · Q4
Regulation of in vitro diagnostics and lab-developed tests
KAISER PERMANENTE via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · RR
Regulation of in vitro diagnostics and lab-developed tests
ROCHE DIAGNOSTICS via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · RR
Regulation of in vitro diagnostics and lab-developed tests
THERMO FISHER SCIENTIFIC via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · RR
Regulation of in vitro diagnostics and lab-developed tests
COLLEGE OF AMERICAN PATHOLOGISTS via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · RR
Regulation of in vitro diagnostics and lab-developed tests
ALEXION PHARMACEUTICALS via MANATT, PHELPS, AND PHILLIPS
2024 · fourth_quarter · RR
Regulation of in vitro diagnostics and lab-developed tests.